Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Leukemia ; 32(11): 2339-2351, 2018 11.
Article in English | MEDLINE | ID: mdl-29743725

ABSTRACT

Despite the pivotal role of MYC in tumorigenesis, the mechanisms by which it promotes cancer aggressiveness remain incompletely understood. Here, we show that MYC transcriptionally upregulates the ubiquitin fusion degradation 1 (UFD1) gene in T-cell acute lymphoblastic leukemia (T-ALL). Allelic loss of ufd1 in zebrafish induces tumor cell apoptosis and impairs MYC-driven T-ALL progression but does not affect general health. As the E2 component of an endoplasmic reticulum (ER)-associated degradation (ERAD) complex, UFD1 facilitates the elimination of misfolded/unfolded proteins from the ER. We found that UFD1 inactivation in human T-ALL cells impairs ERAD, exacerbates ER stress, and induces apoptosis. Moreover, we show that UFD1 inactivation promotes the proapoptotic unfolded protein response (UPR) mediated by protein kinase RNA-like ER kinase (PERK). This effect is demonstrated by an upregulation of PERK and its downstream effector C/EBP homologous protein (CHOP), as well as a downregulation of BCL2 and BCLxL. Indeed, CHOP inactivation or BCL2 overexpression is sufficient to rescue tumor cell apoptosis induced by UFD1 knockdown. Together, our studies identify UFD1 as a critical regulator of the ER stress response and a novel contributor to MYC-mediated leukemia aggressiveness, with implications for targeted therapy in T-ALL and likely other MYC-driven cancers.


Subject(s)
Apoptosis/genetics , Proteins/genetics , Proto-Oncogene Proteins c-myc/genetics , Unfolded Protein Response/genetics , Adaptor Proteins, Vesicular Transport , Animals , Cell Line, Tumor , Disease Progression , Down-Regulation/genetics , Endoplasmic Reticulum/genetics , Endoplasmic Reticulum Stress/genetics , Female , Humans , Intracellular Signaling Peptides and Proteins , Male , Transcription Factor CHOP/genetics , Transcription, Genetic/genetics , Transcriptional Activation/genetics , Ubiquitin/genetics , Up-Regulation/genetics , Zebrafish , eIF-2 Kinase/genetics
2.
Leukemia ; 31(12): 2568-2576, 2017 12.
Article in English | MEDLINE | ID: mdl-28484265

ABSTRACT

While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) have improved dramatically, survival rates for patients with relapsed/refractory disease remain dismal. Prior studies indicate that glucocorticoid (GC) resistance is more common than resistance to other chemotherapies at relapse. In addition, failure to clear peripheral blasts during a prednisone prophase correlates with an elevated risk of relapse in newly diagnosed patients. Here we show that intrinsic GC resistance is present at diagnosis in early thymic precursor (ETP) T-ALLs as well as in a subset of non-ETP T-ALLs. GC-resistant non-ETP T-ALLs are characterized by strong induction of JAK/STAT signaling in response to interleukin-7 (IL7) stimulation. Removing IL7 or inhibiting JAK/STAT signaling sensitizes these T-ALLs, and a subset of ETP T-ALLs, to GCs. The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance. Together, these data suggest that the addition of ruxolitinib or other inhibitors of IL7 receptor/JAK/STAT signaling may enhance the efficacy of GCs in a biologically defined subset of T-ALL.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm , Glucocorticoids/pharmacology , Interleukin-7/metabolism , Janus Kinases/metabolism , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/metabolism , STAT Transcription Factors/metabolism , Signal Transduction/drug effects , Animals , Antineoplastic Agents/therapeutic use , Bcl-2-Like Protein 11/metabolism , Cell Line, Tumor , Dexamethasone/pharmacology , Disease Models, Animal , Humans , Janus Kinase Inhibitors/pharmacology , Mice , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Proto-Oncogene Proteins c-bcl-2/metabolism , Xenograft Model Antitumor Assays
3.
Leukemia ; 30(6): 1365-74, 2016 06.
Article in English | MEDLINE | ID: mdl-26876595

ABSTRACT

Despite the pivotal role of MYC in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) and many other cancers, the mechanisms underlying MYC-mediated tumorigenesis remain inadequately understood. Here we utilized a well-characterized zebrafish model of Myc-induced T-ALL for genetic studies to identify novel genes contributing to disease onset. We found that heterozygous inactivation of a tricarboxylic acid (TCA) cycle enzyme, dihydrolipoamide S-succinyltransferase (Dlst), significantly delayed tumor onset in zebrafish without detectable effects on fish development. DLST is the E2 transferase of the α-ketoglutarate (α-KG) dehydrogenase complex (KGDHC), which converts α-KG to succinyl-CoA in the TCA cycle. RNAi knockdown of DLST led to decreased cell viability and induction of apoptosis in human T-ALL cell lines. Polar metabolomics profiling revealed that the TCA cycle was disrupted by DLST knockdown in human T-ALL cells, as demonstrated by an accumulation of α-KG and a decrease of succinyl-CoA. Addition of succinate, the downstream TCA cycle intermediate, to human T-ALL cells was sufficient to rescue defects in cell viability caused by DLST inactivation. Together, our studies uncovered an important role for DLST in MYC-mediated leukemogenesis and demonstrated the metabolic dependence of T-lymphoblasts on the TCA cycle, thus providing implications for targeted therapy.


Subject(s)
Acyltransferases/physiology , Carcinogenesis , Citric Acid Cycle , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Acyl Coenzyme A/metabolism , Animals , Apoptosis , Cell Line, Tumor , Cell Survival , Humans , Ketoglutaric Acids/metabolism , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/etiology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Zebrafish
4.
Leukemia ; 28(9): 1819-27, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24552990

ABSTRACT

Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphoblasts through poorly defined mechanisms. Normal T-cell progenitors are hypersensitive to mitochondrial apoptosis, a phenotype that is dependent on the expression of proapoptotic BIM. In a conditional zebrafish model, MYC downregulation induced BIM expression in T-lymphoblasts, an effect that was blunted by expression of constitutively active AKT. In human T-ALL cell lines and treatment-resistant patient samples, treatment with MYC or PI3K-AKT pathway inhibitors each induced BIM upregulation and apoptosis, indicating that BIM is repressed downstream of MYC and PI3K-AKT in high-risk T-ALL. Restoring BIM function in human T-ALL cells using a stapled peptide mimetic of the BIM BH3 domain had therapeutic activity, indicating that BIM repression is required for T-ALL viability. In the zebrafish model, where MYC downregulation induces T-ALL regression via mitochondrial apoptosis, T-ALL persisted despite MYC downregulation in 10% of bim wild-type zebrafish, 18% of bim heterozygotes and in 33% of bim homozygous mutants (P=0.017). We conclude that downregulation of BIM represents a key survival signal downstream of oncogenic MYC and PI3K-AKT signaling in treatment-resistant T-ALL.


Subject(s)
Apoptosis Regulatory Proteins/physiology , Membrane Proteins/physiology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Proto-Oncogene Proteins c-akt/physiology , Proto-Oncogene Proteins c-myc/physiology , Proto-Oncogene Proteins/physiology , Animals , Apoptosis/drug effects , Apoptosis Regulatory Proteins/antagonists & inhibitors , Bcl-2-Like Protein 11 , Cell Line, Tumor , Humans , Imidazoles/therapeutic use , Membrane Proteins/antagonists & inhibitors , MicroRNAs/physiology , Phosphatidylinositol 3-Kinases/physiology , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Proto-Oncogene Proteins/antagonists & inhibitors , Quinolines/therapeutic use , Signal Transduction/physiology , Zebrafish
5.
Oncogene ; 30(10): 1252-60, 2011 Mar 10.
Article in English | MEDLINE | ID: mdl-21057528

ABSTRACT

The most common translocation in childhood T-cell acute lymphoblastic leukemia (T-ALL) involves the LMO2 locus, resulting in ectopic expression of the LMO2 gene in human thymocytes. The LMO2 gene was also activated in patients with X-linked Severe Combined Immune Deficiency treated with gene therapy because of retroviral insertion in the LMO2 locus. The LMO2 insertions predisposed these children to T-ALL, yet how LMO2 contributes to T cell transformation remains unclear. The LIM (Lin 11, Isl-1, Mec-3) domain containing LMO2 protein regulates erythropoiesis as part of a large transcriptional complex consisting of LMO2, TAL1, E47, GATA1 and LDB1 that recognizes bipartite E-box-GATA1 sites on target genes. Similarly, a TAL1/E47/LMO2/LDB1 complex is observed in human T-ALL and Tal1 and Lmo2 expression in mice results in disease acceleration. To address the mechanism(s) of Tal1/Lmo2 synergy in leukemia, we generated Lmo2 transgenic mice and mated them with mice that express wild-type Tal1 or a DNA-binding mutant of TAL1. Tal1/Lmo2 and MutTAL1/Lmo2 bitransgenic mice exhibit perturbations in thymocyte development due to reduced E47/HEB transcriptional activity and develop leukemia with identical kinetics. These data demonstrate that the DNA-binding activity of Tal1 is not required to cooperate with Lmo2 to cause leukemia in mice and suggest that Lmo2 may cooperate with Tal1 to interfere with E47/HEB function(s).


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/genetics , DNA-Binding Proteins/genetics , Gene Expression Regulation, Neoplastic/genetics , Leukemia, T-Cell/genetics , Metalloproteins/genetics , Proto-Oncogene Proteins/genetics , T-Lymphocytes/pathology , Adaptor Proteins, Signal Transducing , Animals , Basic Helix-Loop-Helix Transcription Factors/metabolism , Blotting, Southern , Cell Differentiation/genetics , Cell Separation , Chromatin Immunoprecipitation , DNA-Binding Proteins/metabolism , Flow Cytometry , Gene Expression , LIM Domain Proteins , Leukemia, T-Cell/metabolism , Leukemia, T-Cell/pathology , Metalloproteins/metabolism , Mice , Mice, Transgenic , Mutation , Proto-Oncogene Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , T-Cell Acute Lymphocytic Leukemia Protein 1 , Transcription Factor 3/genetics , Transcription Factor 3/metabolism
6.
Cell Death Differ ; 15(2): 344-53, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18007664

ABSTRACT

There is considerable interest in understanding how inflammatory responses influence cell proliferation and cancer. In this study, we show that the receptor-interacting protein (RIP1), a critical mediator of inflammation and stress-induced NF-kappaB activation, regulates the expression of the epidermal growth factor receptor (EGFR). Mouse embryo fibroblasts (MEFs) derived from RIP1 knockout mice express very high levels of the EGFR. Reconstitution of RIP1(-/-) MEFs with RIP1 results in a lowering of EGFR levels. RIP1 influences EGFR at the mRNA level by regulating the EGFR promoter. Expression of RIP1 inhibits the EGFR promoter. RIP1 downregulates EGFR expression by interfering with the function of Sp1, which is a key activator of EGFR transcription. RIP1 suppresses Sp1 activity and overexpression of Sp1 reverses RIP1-mediated repression of the EGFR promoter. RIP1 is present both in the cytoplasm and in the nucleus. RIP1 coimmunoprecipitates with Sp1 in vivo and binds directly to Sp1 in vitro. A RIP1 mutant lacking the death domain fails to suppress Sp1 activity and the EGFR promoter, suggesting a critical role for the RIP1 death domain in EGFR regulation. Thus, our study identifies a new link between inflammatory and growth factor signaling pathways mediated by RIP1 and provides insight into the mechanism used by RIP1 to regulate EGFR levels.


Subject(s)
ErbB Receptors/metabolism , NF-kappa B/metabolism , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , Signal Transduction , Sp1 Transcription Factor/metabolism , Animals , Cell Line, Tumor , Cell Nucleus/metabolism , DNA/metabolism , Down-Regulation , ErbB Receptors/genetics , Humans , Mice , Mice, Knockout , Promoter Regions, Genetic , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptor-Interacting Protein Serine-Threonine Kinases/genetics , Recombinant Proteins/metabolism , Sp1 Transcription Factor/antagonists & inhibitors
7.
Oncogene ; 25(21): 3023-31, 2006 May 18.
Article in English | MEDLINE | ID: mdl-16407836

ABSTRACT

Analysis of the INK4A/ARF locus in human T-ALL patients revealed frequent deletions in exon 2, the exon common to both p16(INK4A) and p14(ARF). Other studies have described selective deletion of exon 1beta of p14(ARF) or methylation of the p16(INK4A) promoter. Therefore, it is unclear from these studies whether loss of p16(INK4A) and/or p14(ARF) contributes to the development of T-ALL. To elucidate the relative contribution of the ink4a/arf locus to T-cell leukemogenesis, we mated our tal1 transgenic mice to ink4a/arf-/-, p16(ink4a)-/-, and p19(arf)-/- mice and generated tal1/ink4a/arf+/-, tal1/p16(ink4a)+/-, and tal1/p19(arf)+/- mice. Each of these mice developed T-cell leukemia rapidly, indicating that loss of either p16(ink4a) or p19(arf) cooperates with Tal1 to induce leukemia in mice. Preleukemic studies reveal that Tal1 expression stimulates entry into the cell cycle and thymocyte apoptosis in vivo. Interestingly, mice expressing a DNA-binding mutant of Tal1 do not exhibit increases in S phase cells. The S phase induction is accompanied by an increase in thymocyte apoptosis in tal1 transgenic mice. Whereas apoptosis is reduced to wild-type levels in tal1/ink4a/arf-/- mice, S phase induction remains unaffected. Thus, Tal1 stimulates cell cycle entry independent of the ink4a/arf locus, but its ability to induce apoptosis is Ink4a/Arf-dependent.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/physiology , Cell Transformation, Neoplastic/genetics , Cyclin-Dependent Kinase Inhibitor p16/physiology , Gene Deletion , Leukemia-Lymphoma, Adult T-Cell/genetics , Proto-Oncogene Proteins/physiology , Tumor Suppressor Protein p14ARF/physiology , Animals , Antigens, CD/analysis , Antigens, Neoplasm/analysis , Apoptosis/genetics , Cell Cycle/genetics , Cyclin-Dependent Kinase Inhibitor p16/deficiency , DNA/metabolism , Exons/genetics , Gene Expression Regulation , Gene Expression Regulation, Leukemic , Genes, p16 , Glycoproteins/physiology , Immunophenotyping , Mice , Mice, Transgenic , Neoplasm Proteins/genetics , Neoplasm Proteins/physiology , Preleukemia/genetics , Preleukemia/metabolism , Protein Binding , Protein Structure, Tertiary , Receptor, Notch1/physiology , S Phase/genetics , T-Cell Acute Lymphocytic Leukemia Protein 1 , T-Lymphocyte Subsets/pathology , Transcription Factors/physiology , Tumor Suppressor Protein p14ARF/deficiency , Tumor Suppressor Protein p14ARF/genetics , Wnt Proteins/physiology
8.
Immunity ; 8(3): 297-303, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9529147

ABSTRACT

The death domain serine/threonine kinase RIP interacts with the death receptors Fas and tumor necrosis receptor 1 (TNFR1). In vitro, RIP stimulates apoptosis, SAPK/JNK, and NF-kappaB activation. To define the physiologic role(s) that RIP plays in regulating apoptosis in vivo, we introduced a rip null mutation in mice through homologous recombination. RIP-deficient mice appear normal at birth but fail to thrive, displaying extensive apoptosis in both the lymphoid and adipose tissue and dying at 1-3 days of age. In contrast to a normal thymic anti-Fas response, rip-/- cells are highly sensitive to TNFalpha-induced cell death. Sensitivity to TNFalpha-mediated cell death in rip-/- cells is accompanied by a failure to activate the transcription factor NF-kappaB.


Subject(s)
Apoptosis , Mitogen-Activated Protein Kinases , NF-kappa B/metabolism , Protein Serine-Threonine Kinases/metabolism , Proteins/metabolism , Tumor Necrosis Factor-alpha/metabolism , Adipose Tissue/pathology , Animals , Calcium-Calmodulin-Dependent Protein Kinases , Cytokines , Failure to Thrive , Genes, Lethal , JNK Mitogen-Activated Protein Kinases , Lymphoid Tissue/pathology , Mice , Mice, Mutant Strains , Protein Serine-Threonine Kinases/genetics , Proteins/genetics , Receptor-Interacting Protein Serine-Threonine Kinases , fas Receptor
9.
EMBO J ; 15(19): 5160-6, 1996 Oct 01.
Article in English | MEDLINE | ID: mdl-8895560

ABSTRACT

Ectopic activation of the TAL-1 gene in T lymphocytes occurs in the majority of cases of human T cell acute lymphoblastic leukemia (T-ALL), yet experiments to date have failed to demonstrate a direct transforming capability for tal-1. The tal-1 gene product is a serine phosphoprotein and basic helix-loop-helix (bHLH) transcription factor known to regulate embryonic hematopoiesis. We have established a transgenic mouse model in which tal-1 mis-expression in the thymus results in the development of clonal T cell lymphoblastic leukemia/lymphoma. Thus, overexpression of tal-1 alone can be transforming, verifying its pathogenic role in human T-ALL. In addition, leukemogenesis is accelerated dramatically by transgenic co-expression of tal-1 and the catalytic subunit of casein kinase IIalpha (CKIIalpha), a serine/threonine protein kinase known to modulate the activity of other bHLH transcription factors. Although tal-1 is a substrate for CKII, the synergy of the tal-1 and CKIIalpha transgenes appears to be indirect, perhaps mediated through the E protein heterodimeric partners of tal-1. These studies prove that dysregulated tal-1 is oncogenic, providing a direct molecular explanation for the malignancies associated with TAL-1 activation in human T-ALL.


Subject(s)
DNA-Binding Proteins/physiology , Leukemia-Lymphoma, Adult T-Cell/etiology , Protein Serine-Threonine Kinases/physiology , Proto-Oncogene Proteins/physiology , Thymus Neoplasms/etiology , Transcription Factors , Animals , Basic Helix-Loop-Helix Transcription Factors , Casein Kinase II , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Disease Models, Animal , Humans , Immunophenotyping , Leukemia-Lymphoma, Adult T-Cell/pathology , Mice , Mice, Transgenic , Oncogenes/genetics , Phosphorylation , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , RNA, Messenger/analysis , RNA, Neoplasm/analysis , T-Cell Acute Lymphocytic Leukemia Protein 1 , Thymoma/chemistry , Thymoma/etiology , Thymoma/pathology , Thymus Gland/chemistry , Thymus Neoplasms/chemistry , Thymus Neoplasms/pathology , Transgenes/genetics
10.
Oncogene ; 8(5): 1249-56, 1993 May.
Article in English | MEDLINE | ID: mdl-8479746

ABSTRACT

Mice reconstituted with BCR/ABL-infected 5-fluorouracil-treated bone marrow are considered a model system for human chronic myelogenous leukemia, a malignancy that arises in hematopoietic stem cells. These animals develop multiple types of hematopoietic tumors, which could arise either from undifferentiated cells that mature during tumor development or from progenitors committed to different lineages. To examine the BCR/ABL-sensitive target cells present in the marrow of mice treated with 5-fluorouracil, we used a single-step in vitro assay. These experiments revealed that both the P210 and P185 BCR/ABL proteins and the related v-abl protein induce lymphoid and myeloid colonies, colony types that mimic two of the prominent types of tumors found in the reconstitution model. The lymphoid colonies were similar to lymphoid colonies found following infection of normal bone marrow with respect to differentiation state and tumorigenicity. The cells in the myeloid colonies were differentiated and non-tumorigenic. Fluorescence-activated cell sorting revealed that most of the lymphoid and myeloid colonies arose from distinct precursors and that the lymphoid colonies arose from B-lineage-committed cells. These data suggest that most of the lymphomas observed in the reconstitution model arise from committed progenitors that are distinct from those involved in the myeloid disease.


Subject(s)
Bone Marrow/pathology , Cell Transformation, Neoplastic , Fluorouracil/pharmacology , Genes, abl , Hematopoietic Stem Cells/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology , Lymphoma/etiology , Animals , Base Sequence , Bone Marrow/immunology , Bone Marrow/microbiology , Fusion Proteins, bcr-abl/genetics , Interleukin-3/pharmacology , Macrophage-1 Antigen/analysis , Mice , Molecular Sequence Data , Phenotype , Proviruses/isolation & purification
11.
Proc Natl Acad Sci U S A ; 87(17): 6649-53, 1990 Sep.
Article in English | MEDLINE | ID: mdl-2204061

ABSTRACT

The v-abl gene in Abelson virus induces pre-B-cell lymphoma in mice while the BCR/ABL oncogene is associated with chronic myelogenous leukemia and some cases of acute lymphocytic leukemia in humans. Understanding the mechanisms by which these oncogenes affect various cell types has been hampered by a paucity of experimental systems that reproduce the range of biological effects associated with them. We have developed an experimental system in which murine hematopoietic stem cell populations are infected with either v-abl or BCR/ABL retroviruses and are used to reconstitute lethally irradiated mice. Irrespective of the form of activated abl, greater than 90% of the animals reconstituted with such cells develop tumors. About 50% of them develop a myeloproliferative syndrome that shares several features with the chronic phase of chronic myelogenous leukemia; the remaining animals succumb to pre-B-cell lymphomas. The myeloproliferative syndrome is characterized by large numbers of clonally derived, infected myeloid cells. This model will allow study of the mechanism by which activated abl genes affect hematopoietic precursors in chronic myelogenous leukemia. Furthermore, our results demonstrate that introduction of an activated abl gene into the appropriate target cell, not the structure of the gene, is the major determinant in myeloid cell specificity.


Subject(s)
Leukemia, Experimental/genetics , Oncogenes , Abelson murine leukemia virus/genetics , Animals , Fusion Proteins, bcr-abl/genetics , Hematopoietic Stem Cells/cytology , Leukemia, Experimental/microbiology , Leukemia, Experimental/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/microbiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Mice , Mice, Inbred BALB C , Moloney murine leukemia virus/genetics , Retroviridae/genetics , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...